EP4724499A2 - Modifizierte schwere immunglobulin variable domänen mit verminderter immunogenität - Google Patents

Modifizierte schwere immunglobulin variable domänen mit verminderter immunogenität

Info

Publication number
EP4724499A2
EP4724499A2 EP24820201.2A EP24820201A EP4724499A2 EP 4724499 A2 EP4724499 A2 EP 4724499A2 EP 24820201 A EP24820201 A EP 24820201A EP 4724499 A2 EP4724499 A2 EP 4724499A2
Authority
EP
European Patent Office
Prior art keywords
polypeptide
amino acid
cytokine receptor
group
vhh
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP24820201.2A
Other languages
English (en)
French (fr)
Inventor
Patrick L. LUPARDUS
Deepti ROKKAM
Michael TOTAGRANDE
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Synthekine Inc
Original Assignee
Synthekine Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Synthekine Inc filed Critical Synthekine Inc
Publication of EP4724499A2 publication Critical patent/EP4724499A2/de
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP24820201.2A 2023-06-07 2024-06-07 Modifizierte schwere immunglobulin variable domänen mit verminderter immunogenität Pending EP4724499A2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202363506797P 2023-06-07 2023-06-07
PCT/US2024/033155 WO2024254562A2 (en) 2023-06-07 2024-06-07 Modified immunoglobulin variable heavy domains having reduced immunogenicity

Publications (1)

Publication Number Publication Date
EP4724499A2 true EP4724499A2 (de) 2026-04-15

Family

ID=93796476

Family Applications (1)

Application Number Title Priority Date Filing Date
EP24820201.2A Pending EP4724499A2 (de) 2023-06-07 2024-06-07 Modifizierte schwere immunglobulin variable domänen mit verminderter immunogenität

Country Status (6)

Country Link
EP (1) EP4724499A2 (de)
KR (1) KR20260021032A (de)
CN (1) CN121941708A (de)
AU (1) AU2024285577A1 (de)
IL (1) IL324785A (de)
WO (1) WO2024254562A2 (de)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20230148844A (ko) * 2016-03-29 2023-10-25 유니버시티 오브 써던 캘리포니아 암을 표적하는 키메라 항원 수용체
MX2023002107A (es) * 2020-08-21 2023-03-15 Novartis Ag Composiciones y metodos para la generacion in vivo de celulas que expresan car.
MX2023003304A (es) * 2020-09-21 2023-05-09 Systimmune Inc Complejo de union de egfr y metodo de fabricacion y uso del mismo.
CN115703829B (zh) * 2021-08-16 2025-01-10 厦门大学 针对SARS-CoV-2的单域抗体及其用途

Also Published As

Publication number Publication date
AU2024285577A1 (en) 2025-12-04
IL324785A (en) 2026-01-01
WO2024254562A3 (en) 2025-03-20
WO2024254562A2 (en) 2024-12-12
KR20260021032A (ko) 2026-02-12
CN121941708A (zh) 2026-04-28

Similar Documents

Publication Publication Date Title
US12221487B2 (en) Nucleic acids encoding CX3CR1-binding polypeptides comprising immunoglobulin single variable domains
CN105001330B (zh) 生产异源多聚体蛋白质
CN104271602A (zh) 双特异性抗体
CA2904532A1 (en) Anti-cd25 antibodies and their uses
US20150010538A1 (en) Anti-cd25 antibodies and their uses
EP4294829A1 (de) Anti-cd123-bindende moleküle und verwendungen davon
TW202311295A (zh) 一種抗原結合分子
AU2012214274B2 (en) CH2 domain template molecules derived from rational grafting of donor loops onto CH2 scaffolds
CN118638234B (zh) 抗bdca2抗体及其制备方法和应用
Fredericks et al. Identification of potent human anti‐IL‐1RI antagonist antibodies
JP2023507280A (ja) ヒトｉｌ－１３及びｉｌ－１７に対する結合特異性を有する多重特異性抗体
AU2024285577A1 (en) Modified immunoglobulin variable heavy domains having reduced immunogenicity
WO2025026282A1 (en) Modified type e multi-specific antibodies
WO2025077834A1 (en) Anti-il-4ra antibodies and uses thereof
WO2025185656A1 (zh) 抗pd-l1和cd40双特异性抗体及其用途
JP2025532504A (ja) 抗ｉｌｔ４抗体及びその医薬的使用
HK1227904A1 (en) Production of t cell retargeting hetero-dimeric immunoglobulins
HK1227904A (en) Production of t cell retargeting hetero-dimeric immunoglobulins

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20251205

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC ME MK MT NL NO PL PT RO RS SE SI SK SM TR